These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 36230691)

  • 1. Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors.
    McClellan K; Chen EY; Kardosh A; Lopez CD; Del Rivero J; Mallak N; Rocha FG; Koethe Y; Pommier R; Mittra E; Pegna GJ
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review.
    Maqsood MH; Tameez Ud Din A; Khan AH
    Cureus; 2019 Jan; 11(1):e3986. PubMed ID: 30972265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Strosberg JR
    CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lutetium oxodotreotide (
    Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
    BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of lutetium (
    Palmer J; Leeuwenkamp OR
    World J Clin Cases; 2020 Oct; 8(20):4793-4806. PubMed ID: 33195647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors.
    Patel D; Chan D; Cehic G; Pavlakis N; Price TJ
    Expert Rev Endocrinol Metab; 2016 Jul; 11(4):311-327. PubMed ID: 30058926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
    Boucher JE; Sommers R
    Clin J Oncol Nurs; 2018 Oct; 22(5):565-568. PubMed ID: 30239510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical outcomes of [
    Iqbal S; Zhuang E; Raj M; Bahary N; Monga DK
    Front Oncol; 2024; 14():1393317. PubMed ID: 38817893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Uri I; Grozinsky-Glasberg S
    Clin Diabetes Endocrinol; 2018; 4():16. PubMed ID: 30009041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH; Eriksson B
    Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update in the management of gastroenteropancreatic neuroendocrine tumors.
    Sedlack AJH; Varghese DG; Naimian A; Yazdian Anari P; Bodei L; Hallet J; Riechelmann RP; Halfdanarson T; Capdevilla J; Del Rivero J
    Cancer; 2024 Sep; 130(18):3090-3105. PubMed ID: 39012928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Spada F; Campana D; Lamberti G; Laudicella R; Dellamano R; Dellamano L; Leeuwenkamp O; Baldari S
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2037-2048. PubMed ID: 34950969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Das S; Dasari A
    Ther Adv Med Oncol; 2021; 13():17588359211018047. PubMed ID: 34093744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review.
    Camus B; Cottereau AS; Palmieri LJ; Dermine S; Tenenbaum F; Brezault C; Coriat R
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33803817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives.
    Modica R; Liccardi A; Minotta R; Cannavale G; Benevento E; Colao A
    Expert Rev Endocrinol Metab; 2022 Sep; 17(5):389-403. PubMed ID: 35822906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE.
    Prétot D; Engel-Bicik I; Kenkel D; Kaufmann PA; Treyer V; Siebenhüner AR
    J Gastrointest Oncol; 2023 Jun; 14(3):1204-1217. PubMed ID: 37435198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours.
    Srirajaskanthan R; Toumpanakis C; Meyer T; Caplin ME
    Aliment Pharmacol Ther; 2009 Jun; 29(11):1143-54. PubMed ID: 19298583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.